Evidence map›Paper›PMID 33721539›Full record

ArticleAnnals of internal medicine2021

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.

Caleb P Skipper, David R Boulware

Registry-linked trialAbstract readComment
PubMed Publisher
In one paragraph

Article in Annals of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04308668 (Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04308668 phase3completednot on this map

Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial

TypeinterventionalSponsorUniversity of MinnesotaRan2020 to 2020Enrolled1,312ConditionsCorona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, CoronavirusArmsHydroxychloroquine, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2022
    Review
  4. COVID-19: breaking down a global health crisis.Annals of clinical microbiology and antimicrobials · 2021
    Review
  5. Azithromycin for severe COVID-19.Lancet (London, England) · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Caleb P SkipperUniversity of Minnesota, Minneapolis, Minnesota.
David R BoulwareUniversity of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-4715-0060
University of Minnesota System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Coronavirus InfectionsCOVID-19 Drug TreatmentAdultHumansHydroxychloroquineSARS-CoV-2Hydroxychloroquine

Identifiers

PMID33721539
OpenAlexW3137187469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.